Prokidney CORP Form 4 insider transactions

Brian Jg Pereira, a Director of Prokidney Corp., reported multiple transactions in common stock on August 4, 2026.

ProKidney Corp. reports the grant of employee stock options to Chief Technical Officer Kenneth Thomas Locke.

Chief Legal Officer Todd C. Girolamo converted 163,857 shares of Class B Common Stock and paired units into Class A Common Stock.

Director Alan Lotvin was granted 135,000 stock options under ProKidney Corp.'s non-employee director compensation policy.

Director Jose Ignacio Jimenez Santos was granted 135,000 stock options as part of ProKidney Corp.'s non-employee director compensation policy.

Director Jennifer A. Fox was granted 135,000 stock options in ProKidney Corp as part of the company's non-employee director compensation policy.

Director William F. Doyle was granted 135,000 stock options in ProKidney Corp. as part of the company's non-employee director compensation policy.

Director Pablo Legorreta was granted 135,000 stock options in ProKidney Corp as part of the company's non-employee director compensation policy.

Director Brian J.G. Pereira was granted 135,000 stock options in ProKidney Corp. as part of the company's non-employee director compensation policy.

Control Empresarial de Capitales S.A. de C.V. converted 63.1 million paired interests into Class A common shares of ProKidney Corp.

PROKIDNEY Corp.'s Chief Financial Officer, James Coulston, was granted 600,000 employee stock options with an exercise price of $2.24, vesting over four years.

PROKIDNEY's Chief Regulatory Officer, Darin J. Weber, was granted 400,000 employee stock options with an exercise price of $2.24, vesting over four years starting March 1, 2026.

PROKIDNEY Corp.'s Chief Legal Officer, Todd C. Girolamo, was granted 600,000 employee stock options with an exercise price of $2.24, vesting over four years.

PROKIDNEY Corp. CEO Bruce Culleton received a grant of 3 million employee stock options with an exercise price of $2.24, vesting over four years starting March 1, 2026.

A director at ProKidney Corp. sold over 750,000 shares of Class A Common Stock through trusts in pre-arranged transactions on November 12 and 13, 2025.

Aaron Cowen, a director of ProKidney Corp., has filed an exit Form 4 indicating he is no longer a beneficial owner of more than 10% of the company's Class A common stock, a change attributed to an increase in outstanding shares.

PROKIDNEY Corp.'s Chief Regulatory Officer, Darin J. Weber, sold 103,480 shares of Class A Common Stock for $3.02 per share, completing a pre-arranged Rule 10b5-1 trading plan and divesting all direct holdings.

A recent SEC Form 4 filing reveals that Pablo G. Legorreta, a Director and 10% owner of ProKidney Corp., through his controlled affiliate Tolerantia, LLC, completed an exchange of paired interests for Class A Ordinary Shares, which were subsequently distributed to unaffiliated investors.

PROKIDNEY Corp. has reported that Director and 10% owner Pablo G. Legorreta was granted 125,862 stock options with an exercise price of $0.72 per share.

PROKIDNEY Corp. Director Uma Sinha was granted 125,862 stock options with an exercise price of $0.72, vesting based on time or the next annual general shareholder meeting, as part of the company's non-employee director compensation policy.

PROKIDNEY Corp. Director Brian Pereira was granted 125,862 stock options with an exercise price of $0.72, vesting on the sooner of one year or the next annual general shareholder meeting.

PROKIDNEY Corp. Director Jose Ignacio Jimenez Santos was granted 125,862 stock options with an exercise price of $0.72, vesting on the sooner of one year or the next annual general shareholder meeting.

PROKIDNEY Corp. Director Jennifer A. Fox was granted 125,862 stock options with an exercise price of $0.72, as part of the company's non-employee director compensation policy.

PROKIDNEY Corp. Director William F. Doyle was granted 125,862 stock options as part of the company's non-employee director compensation policy.

PROKIDNEY Corp. Director Alan Lotvin was granted 125,862 stock options with an exercise price of $0.72, aligning his interests with the company's performance.

Control Empresarial de Capitales S.A. de C.V. reports acquiring additional Class A Ordinary Shares of ProKidney Corp., increasing their beneficial ownership.

Control Empresarial de Capitales S.A. de C.V. reports the acquisition of 25,000 Class A Ordinary Shares of ProKidney Corp. at a weighted average price of $0.7476 per share.

Control Empresarial de Capitales S.A. de C.V. purchased 100,000 Class A Ordinary Shares of ProKidney Corp. at an average price of $0.7482 per share.

Control Empresarial de Capitales S.A. de C.V., associated with the Slim Family, has increased its holdings in ProKidney Corp. through open market purchases of Class A Ordinary Shares.

Control Empresarial de Capitales S.A. de C.V. reports acquiring additional Class A Ordinary Shares of ProKidney Corp., increasing their beneficial ownership.